ERBB2 and breast cancer: In terms of drug side effects, an RWS evaluating the cardiac safety of intravenous trastuzumab in patients with HER2+ BC found that the incidence of symptomatic congestive heart failure and cardiac death was consistent with the conclusions of randomized clinical trials [26].